Therapeutic manipulation of glucocorticoid metabolism in cardiovascular disease
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
The therapeutic potential for manipulation of glucocorticoid metabolism in cardiovascular disease was revolutionized by the recognition that access of glucocorticoids to their receptors is regulated in a tissue‐specific manner by the isozymes of 11β‐hydroxysteroid dehydrogenase. Selective inhibitors of 11β‐hydroxysteroid dehydrogenase type 1 have been shown recently to ameliorate cardiovascular risk factors and inhibit the development of atherosclerosis. This article addresses the possibility that inhibition of 11β‐hydroxsteroid dehydrogenase type 1 activity in cells of the cardiovascular system contributes to this beneficial action. The link between glucocorticoids and cardiovascular disease is complex as glucocorticoid excess is linked with increased cardiovascular events but glucocorticoid administration can reduce atherogenesis and restenosis in animal models. There is considerable evidence that glucocorticoids can interact directly with cells of the cardiovascular system to alter their function and structure and the inflammatory response to injury. These actions may be regulated by glucocorticoid and/or mineralocorticoid receptors but are also dependent on the 11β‐hydroxysteroid dehydrogenases which may be expressed in cardiac, vascular (endothelial, smooth muscle) and inflammatory (macrophages, neutrophils) cells. The activity of 11β‐hydroxysteroid dehydrogenases in these cells is dependent upon differentiation state, the action of pro‐inflammaotory cytokines and the influence of endogenous inhibitors (oxysterols, bile acids). Further investigations are required to clarify the link between glucocorticoid excess and cardiovascular events and to determine the mechanism through which glucocorticoid treatment inhibits atherosclerosis/restenosis. This will provide greater insights into the potential benefit of selective 11β‐hydroxysteroid dehydrogenase inhibitors in treatment of cardiovascular disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pitt, B., Remme, W., Zannad, F., Neaton, J., Martinez, F., Roniker, B., Bittman, R., Hurley, S., Kleiman, J., & Gatlin, M. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030207 · Cited by 4,941
Guide to receptors and channels (GRAC), 5th edition
Alexander, S., Mathie, A., & Peters, J. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01649_1.x · Cited by 1,947
A transgenic model of visceral obesity and the metabolic syndrome
Masuzaki, H., Paterson, J., Shinyama, H., Morton, N. M., Mullins, J. J., Seckl, J. R., & Flier, J. S. (2001) · Science · doi:10.1126/science.1066285 · Cited by 1,766 · cited 4×
“, 1997; 1999) and over-expression (Masuzaki et al., 2001; 2003; Paterson et al., 2004) of 11-HSD isozymes has been invaluable in this respect.”
BackgroundInfluentialFetal and placental size and risk of hypertension in adult life.
Barker, D. J., Bull, A. R., Osmond, C., & Simmonds, S. J. (1990) · BMJ · doi:10.1136/bmj.301.6746.259 · Cited by 1,728
Mineralocorticoid action: target tissue specificity is enzyme, not receptor, mediated
Funder, J. W., Pearce, P. T., Smith, R., & Smith, A. I. (1988) · Science · doi:10.1126/science.2845584 · Cited by 1,628 · cited 1×
“Rather, it was shown that 11-HSD activity was essential for maintaining aldosterone selectivity of MR (Edwards et al., 1988; Funder et al., 1988).”
Background11β-Hydroxysteroid dehydrogenase type 1: a tissue specific regulator of glucocorticoid response
Tomlinson, J. W., Walker, E. A., Bujalska, I. J., Draper, N., Lavery, G. G., Cooper, M. S., Hewison, M., & Stewart, P. M. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0031 · Cited by 969 · cited 4×
“In addition, it is possible that some antiatherosclerotic interventions owe part of their effectiveness to regulation of 11-HSDs as PPAR-a agonists, such as fibrates (which are important agents for treating dyslipidaemia) reduce 11-HSD1 expression and activity in murine liver (Hermanowski-Vosatka et al., 2000).”
InfluentialFeast and Famine: Critical Role of Glucocorticoids with Insulin in Daily Energy Flow
Dallman, M. F., Strack, A. M., Akana, S. F., Bradbury, M. J., Hanson, E. S., Scribner, K. A., & Smith, M. (1993) · Frontiers in Neuroendocrinology · doi:10.1006/frne.1993.1010 · Cited by 796 · cited 2×
“Most of the indirect systemic effects of glucocorticoids lead to an increase in cardiovascular risk factors and, therefore, are linked to the prognosis of increased cardiovascular events (Dallman et al., 1993; Andrews and Walker, 1999; Walker, 2007b).”
BackgroundDoes central obesity reflect “Cushing's disease of the omentum”?
Bujalska, I. J., Kumar, S., & Stewart, P. M. (1997) · The Lancet · doi:10.1016/s0140-6736(96)11222-8 · Cited by 753 · cited 2×
“Intact cells or organs [including liver (Jamieson et al., 1995; 2000; Ricketts et al., 1998), adipose tissue (Bujalska et al., 1997), neurones (Rajan et al., 1996) and vascular smooth British Journal of Pharmacology (2009) 156 689–712 muscle (Hatakeyama et al., 1999)] generally do not exhibit the…”
BackgroundGlucocorticoids and insulin resistance: old hormones, new targets
ANDREWS, R. C., & WALKER, B. R. (1999) · Clinical Science · doi:10.1042/cs0960513 · Cited by 731 · cited 1×
“Most of the indirect systemic effects of glucocorticoids lead to an increase in cardiovascular risk factors and, therefore, are linked to the prognosis of increased cardiovascular events (Dallman et al., 1993; Andrews and Walker, 1999; Walker, 2007b).”
BackgroundSelf-citationMorbidity and mortality in Cushing's disease: an epidemiological approach.
Etxabe, J., & Vazquez, J. A. (1994) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1994.tb02486.x · Cited by 622
Cited by
Coronary stents: historical development, current status and future directions
Iqbal, J., Gunn, J., & Serruys, P. W. (2013) · British Medical Bulletin · doi:10.1093/bmb/ldt009 · Cited by 319
Self-citationMetabolic nuclear receptor signaling and the inflammatory acute phase response
Venteclef, N., Jakobsson, T., Steffensen, K. R., & Treuter, E. (2011) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2011.04.004 · Cited by 99
Obesity and cortisol: New perspectives on an old theme
van Rossum, E. F. C. (2017) · Obesity · doi:10.1002/oby.21774 · Cited by 76
Correia-Branco, A., Keating, E., & Martel, F. (2015) · Reproductive Sciences · doi:10.1177/1933719114542012 · Cited by 55
“In fact, GC administration reduces fetal growth and stably alters gene expression in a manner that favors increased production and storage of energy substrates, with increased risk of hyperlipidemia, hyperglycemia, and hypertension.(62,63) Moreover, human fetal-blood cortisol levels are increased in FGR, implicating e…”
Background
Metadata
- Authors
- Hadoke, P. W. F., Iqbal, J., & Walker, B. R.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2009-03
- Volume
- 156
- Issue
- 5
- Pages
- 689-712
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W1550426019
- Cited by
- 99
- References
- 22
- FWCI
- 5.87
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Therapeutic manipulation of glucocorticoid metabolism in cardiovascular disease. https://app.cochat.ai/papers/10.1111/j.1476-5381.2008.00047.x
- The paper
- Hadoke, P. W. F., Iqbal, J., & Walker, B. R. (2009). Therapeutic manipulation of glucocorticoid metabolism in cardiovascular disease. British Journal of Pharmacology. https://doi.org/10.1111/j.1476-5381.2008.00047.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.